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Abstract: Semaphorin3A is a secreted protein known to be involved in organogenesis, immune 
responses and cancer. In the kidney, semaphorin3A is expressed in the glomerular podocytes, 
distal tubules and collecting tubules, and believed to play a role in the regulation of the kidney 
development and function. We examined the serum and urinary semaphorin3A levels in 72 
patients with renal disease and 5 healthy volunteers. The patients had been diagnosed with 
thin basement membrane disease (n=4), minimal change nephrotic syndrome (MCNS; n=22), 
IgA nephritis (n=21), membranous nephropathy (n=16) and focal segmental glomerular scle-
rosis (n=9). The level of urinary semaphorin3A in MCNS patients tended to be relatively high 
among all disease groups. We also investigated the urinary semaphorin3A level in 7 patients 
with MCNS from disease onset to remission during the drug therapy. MCNS patients in pre-
remission states had higher urinary semaphorin3A levels than those in post-remission states 
receiving immunosuppressive therapies. These results suggested that the urinary semaphorin3A 
level correlates with the MCNS activity. Semaphorin3A has the potential as a biomarker for 
MCNS to clarify the reactivity for therapy and may be useful in examining other glomerular 
diseases with proteinuria as well.
Keywords: semaphorin3A, biomarker, minimal change nephrotic syndrome
Introduction
The pathological findings in renal diseases with proteinuria, such as minimal change 
nephrotic syndrome (MCNS), membranous nephropathy (MN), IgA nephritis (IgA-N) 
and focal segmental glomerular sclerosis (FSGS), as well as other cases of glomerular 
nephritis are podocyte foot process effacement and slit diaphragm absence.1 The dam-
age to podocytes is believed to cause proteinuria, and long-standing proteinuria leads 
to the deterioration of the nephron, which results in glomerular sclerosis and renal 
fibrosis. To evaluate the damage associated with these renal pathological findings, a 
biomarker capable of determining the precise state of the renal function at a given 
moment is needed. Urinary podocyte loss and urinary nephrin have been studied as 
candidate biomarkers of diabetic nephropathy and other nephropathies.2,3 However, no 
specific biomarker that relates to the activity of glomerular diseases has been identified.
Semaphorins are guidance proteins that influence axonal progression.4 There are 
seven subclasses that are distinguished by the differences in several domains.5 Sema-
phorin3A is a member of the semaphorin family that is involved in nerve cell migration, 
angiogenesis, regulation of the immune system and cancer progression.5–8 With regard 
to the kidney, semaphorin3A is reported to be an endogenous antagonist of ureteric 
bud branching and a regulator of endothelial cell number and podocyte differentiation 
Correspondence: Shinji Kitamura
Department of Medicine and Clinical 
Science, Okayama University Graduate 
School of Medicine, Dentistry and 
Pharmaceutical Sciences, Kita-ku, 
Okayama 700–8558, Japan
Tel +81 86 235 7235
Fax +81 86 222 5214
Email s-kita@md.okayama-u.ac.jp
Journal name: International Journal of Nephrology and Renovascular Disease
Article Designation: ORIGINAL RESEARCH
Year: 2017
Volume: 10
Running head verso: Inoue-Torii et al
Running head recto: Urinary semaphorin3A levels in MCNS
DOI: http://dx.doi.org/10.2147/IJNRD.S132980
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
International Journal of Nephrology and Renovascular Disease 2017:10submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
168
Inoue-Torii et al
during glomerular development.9,10 Semaphorin3A and its 
receptors neuropilin-1 and neuropilin-2 are expressed on 
differentiated podocytes, distal tubules and collecting duct 
cells.11,12 Recombinant semaphorin3A decreases the expres-
sion of podocin with nephrin and CD2-associated protein 
in vitro.12 Additionally, recombinant semaphorin3A admin-
istration causes proteinuria in adult mice.13 The associated 
pathological findings are podocyte foot process effacement 
and fusion in the glomeruli.13 Altogether, semaphorin3A is 
believed to play various roles in the podocyte maintenance 
of the slit diaphragm.
An interesting report suggested that semaphorin3A might 
represent a biomarker of acute kidney injury (AKI).14 Another 
report said that hypertensive patients with albuminuria with 
or without a reduced estimated glomerular filtration rate 
had increased urinary semaphorin3A levels.15 Furthermore, 
urinary semaphorin3A from diabetic patients was reported to 
increase with the deterioration of nephropathy, and in basic 
research, the suppression of semaphorin3A was suggested 
to inhibit the renal damage of diabetic nephropathy.16 From 
these reports, semaphorin3A might influence the pathophysi-
ology in the course of kidney disease, with respect to not only 
interstitial damage but also glomerular diseases. Therefore, 
we hypothesized that semaphorin3A played some roles in 
glomerular diseases with proteinuria.
In this study, we analyzed the serum and urinary sema-
phorin3A levels of patients with glomerular disease who 
were examined and treated at the nephrology department in 
our hospital and other hospitals. In addition, we followed up 
several patients who received immunosuppressive therapy. 
Through these efforts, we clarified the association between 
MCNS disease states and urinary semaphorin3A.
Materials and methods
Patient population
This study is a multi-institutional, retrospective analysis 
evaluating patients’ serum and urine samples. We studied 
72 Japanese patients admitted to the Okayama University 
Hospital and 3 other facilities for the investigation of uri-
nary abnormalities or renal failure between January 2011 
and January 2016. The patients were 17–90 years of age. 
At the time of renal biopsy in our hospital, we collected 
serum and urine samples from the patients. We diagnosed 
each nephropathy according to the pathological findings 
(immunofluorescence, light microscopic and electron 
microscopic analyses) of renal biopsy and the clinical 
findings. The patients were diagnosed with thin basement 
membrane disease (TBM), MCNS, IgA-N, MN or FSGS. 
In addition, we followed seven patients with MCNS from 
disease onset to remission during drug therapy to examine 
the changes in the urinary semaphorin3A levels. All the 
data were retrospectively obtained from electronic medical 
charts. Five healthy volunteers from Okayama University 
also participated in this study.
The study was approved by the institutional review board 
of the Okayama University Graduate School of Medicine, 
Dentistry and Pharmaceutical Sciences, Japanese Red Cross 
Society Himeji Hospital, Shigei Medical Research Hospital 
and Kurashiki Central Hospital. We performed serum and 
urine sampling as part of approved protocols (approval num-
bers 843 and 2063). We obtained written informed consent 
from all subjects for this study. This study was registered with 
the Clinical Trial Registry of the University Hospital Medical 
Information Network (registration number UMIN000013422 
and UMIN000010104). All the patient samples were stored 
at −80°C.
Semaphorin3A quantification by 
enzyme-linked immunosorbent 
assay
We measured the level of semaphorin3A in serum and urine 
using an enzyme-linked immunosorbent assay kit (MyBio-
Source, San Diego, CA, USA). Microtiter plates were 
precoated with an antibody. The serum and urine samples, 
standards and a buffered solution were added to the plates. 
After the enzyme conjugate was added and thoroughly 
mixed, the plates were covered and incubated for 1 h at 
room temperature. After washing the plates, we added two 
types of substrates to the plates. The enzyme and substrate 
were incubated to react for 15 min. Following mixing with 
the sulfuric acid solution to arrest the reaction, we evaluated 
the levels of semaphorin3A by measuring the optical density 
at 450 nm using a microplate reader (Thermo Scientific, 
Yokohama, Japan).
N-Acetyl-β-d-glucosaminidase (NAG) 
quantification by a colorimetric analysis
We measured patients’ urinary NAG level by determining the 
concentration of a chemical substance in a method called col-
orimetric analysis. We used the β-N-acetylglucosaminidase 
assay kit (Sigma-Aldrich, St. Louis, MO, USA). The assay is 
based on the hydrolysis of the NAG substrate, 4-nitrophenl 
N-acetyl-β-d-glucosaminide by the enzyme. First, the sub-
strate solution and the standard solution were equilibrated 
to 37°C by incubating for 5 min. After the substrate solution 
was added to each sample, the samples were incubated for 
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10 min at 37°C. The stop solution was then added to each 
well. The absorption was measured at 405 nm.
Immunohistochemistry analysis
Immunohistochemistry was performed on formalin-fixed, 
paraffin-embedded sections. For the immunohistochemistry 
of semaphorin3A and neuropilin-1, paraffin-embedded sec-
tions (4 μm) were dewaxed and rehydrated. Antigen retrieval 
was performed in a microwave oven for 5 min. Endogenous 
peroxidase was quenched with 3% H
2
O
2
 for 30 min, after 
which the sections were blocked with 3% bovine serum 
albumin (Sigma-Aldrich) for 30 min. The sections were 
first incubated with primary antibody for semaphorin3A 
(ab23393; Abcam, Cambridge, MA, USA) and neuropilin-1 
(ab81321; Abcam) in a humidity cabinet for 1 h at room 
temperature, and the negative controls were incubated in 
the normal serum for the same time. Next, the sections 
were incubated with biotin-conjugated goat anti-rabbit IgG 
antibody (Nichirei Bioscience, Tokyo, Japan) for 30 min 
at room temperature. The sections were then incubated for 
30 min using the Vectastain ABC Elite reagent kit (Vector 
Laboratories, Burlingame, CA, USA) and developed with 
diaminobenzidine (Vector Laboratories) for 5 min. All slides 
were counterstained with hematoxylin, and the images were 
recorded using an FSX-100 microscope (Olympus, Tokyo, 
Japan).
Statistical analysis
All data are expressed as the means ± SD. Multiple com-
parisons were performed by the Kruskal–Wallis method. 
Analyses of the correlation between urinary semaphorin3A 
and urinary protein were performed by Spearman’s correla-
tion coefficient. The changes in the urinary semaphorin3A 
level between onset and remission in MCNS patients was 
analyzed by Wilcoxon signed-rank test. A p-value of <0.05 
was regarded as statistically significant. The data were 
analyzed using the IBM SPSS Statistics software program, 
version 22 (IBM, Armonk, NY, USA).
Results
Patients’ characteristics
Four patients (5.6%) were diagnosed with TBM, 22 (30.6%) 
with MCNS, 21 (29.2%) with IgA-N, 16 (22.2%) with MN and 
9 (12.5%) with FSGS (Table 1). The diagnosis was established 
based on the clinical and pathological findings (immunofluo-
rescence, light microscopic and electron microscopic analyses). 
The TBM, IgA-N and MN patients did not receive any treatment 
for their renal disorder before sampling. In contrast, 15 patients 
(68%) in the MCNS group started treatment with steroids 
and/or immunosuppressive drugs before sampling of the serum 
and urine, and about half of FSGS patients (55.6%) received 
immunosuppressive therapy for complicated diseases and 
a clinical diagnosis of FSGS before sampling. Patients in the 
MN group tended to be older than in MCNS and IgA-N groups. 
The degree of proteinuria in the MCNS, MN and FSGS groups 
was significantly higher than in the healthy control group. Of the 
15 patients (68%) in the MCNS group who had already started 
immunosuppressive therapy, 4 had already achieved remission 
by the time of sampling, and the remaining 11 exhibited reduced 
levels of urinary protein. Nephrotic-range proteinuria (≥3.5 g) 
was evident in 13 patients (59%) in the MCNS group.
Association of urinary semaphorin3A 
with remission in MCNS
The urinary semaphorin3A level in MCNS was statistically 
higher than in control (Figure 1A). We suspected there might 
be a correlation between semaphorin3A and MCNS activ-
ity, so we tracked the urinary semaphorin3A level of seven 
MCNS patients from onset to remission. Time after remission 
ranged from about 2 weeks to 3 years. The levels of urinary 
semaphorin3A at onset were significantly higher than those 
at remission (312.14±220.98 vs 43.67±26.66 ng/g·Cr; Figure 
1B and C respectively). This result suggests the urinary sema-
phorin3A might reflect the acute functional or morphological 
change of glomeruli of MCNS. Urinary semaphorin3A levels 
in IgA-N and MN groups were also higher than in control 
(Figure 1A). Then we also examined the urinary N-acetyl-β-
Table 1 Characteristics of the patients and controls
Characteristic TBM (n=4) MCNS (n=22) IgA-N (n=21) MN (n=16) FSGS (n=9) Control (n=5)
Age (years) 47.8±8.3 45.7±24.0* 40.7±16.2** 66.7±17.3 49.6±15.8 37.0±7.5
Male (%) 2 (50.0) 13 (59.1) 8 (40.1) 11 (68.8) 6 (67) 3 (60)
Cr (mg/dL) 0.65±0.15 0.88±0.40 1.00±0.58 0.96±0.36 1.13±0.39 0.80±0.15
uTP/uCr (g/g⋅Cr) 0.34±0.13 5.28±4.30†† 2.00±2.00 6.62±6.20†† 3.11±2.52† 0.03±0.02
Drug therapy (%) 0 15 (68.0) 0 0 5 (55.6) 0
Notes: Mean±SD are reported for the continuous variables. Percentages are reported for the categorical variables. *p<0.05 versus MN, **p<0.01 versus MN, †p<0.05 versus 
control, ††p<0.01 versus control.
Abbreviations: Cr, serum creatinine; FSGS, focal segmental glomerular sclerosis; IgA-N, IgA nephritis; MCNS, minimal change nephrotic syndrome; MN, membranous 
nephropathy; TBM, thin basement membrane disease.
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d-glucosaminidase (NAG) of each patient as a biomarker of 
damage to the proximal tubules. We also observed significant 
increases in MCNS, IgA-N and MN groups compared with 
control (Figure S1A). These findings suggest that the differ-
ence in the urinary levels of semaphorin3A might reflect the 
degree of interstitial damage induced by each glomerular 
disease. The serum semphorin3A levels in MCNS and MN 
patients were higher than in control (Figure S1B).
Localization of semaphorin3A and 
neuropilin-1 in MCNS
Immunohistochemical examinations revealed semapho-
rin3A in the glomerular podocytes, distal tubules and 
collecting tubules (Figure 2A: in glomerulus, Figure 2B: 
in tubules) in the kidneys of MCNS patients. The distribu-
tions exhibited in patients with other glomerular diseases 
and TBM, which was considered almost normal clini-
cally, were the same as that observed for MCNS kidney 
 (Figure S2A, C, E and G: in glomerulus, Figure 2B, D, F 
and H: in tubules). Additionally, one of the semaphorin3A 
receptors, neuropilin-1, was also detected in the podocytes, 
the luminal side of the distal tubules and the collecting 
tubules in the MCNS group (Figure 2C: in glomerulus, 
Figure 2D: in tubules). In glomerular diseased and TBM 
kidneys, neuropilin-1-positive cells were similarly mainly 
detected in the glomerular podocytes and in the luminal 
side of the distal tubular cells (Figure S3A, C, E and G: in 
glomerulus, Figure 3B, D, F and H: in tubules).
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Figure 1 Urinary semaphorin3A levels and the change of the urinary semaphorin3A level in MCNS patients between onset and remission.
Notes: (A) Urinary semaphorin3A levels in the MCNS, IgA-N and MN groups are higher than in control. *p<0.05, **p<0.01. (B) The urinary semaphorin3A level at disease 
onset (312.1±221.0 ng/mL) was significantly higher than at remission (43.8±26.7 ng/mL) in patients with MCNS (n=7). *p<0.05. (C) The urinary semaphorin3A level was 
reduced by treatment in MCNS patients (n=7).
Abbreviations: FSGS, focal segmental glomerular sclerosis; IgA-N, IgA nephritis; MCNS, minimal change nephrotic syndrome; MN, membranous nephropathy; TBM, thin 
basement membrane disease.
Figure 2 Immunohistochemical localization of semaphorin3A and neuropilin-1 in 
the glomerulus and renal tubules in patients with MCNS.
Notes: (A) The podocytes exhibit partial positive staining in the glomerulus. (B) 
The renal tubules, which appear to be distal or collecting tubules in the absence 
of a brush border, are positively stained. (C) The podocytes exhibit focal positive 
staining for neuropilin-1 in the glomerulus. (D) The renal tubules are positively 
stained, particularly at the luminal side for neuropilin-1.
Abbreviation: MCNS, minimal change nephrotic syndrome.
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Urinary semaphorin3A levels vs urinary 
protein levels
Some studies have reported a correlation with urinary sema-
phorin3A and urinary protein or albuminuria in diabetic 
nephropathy and chronic kidney disease.15,16 We therefore 
analyzed the correlation between urinary semaphorin3A and 
urinary protein. None of the renal disease groups exhibited 
similar tendencies (Table 2). Nonsignificant correlation was 
observed in the subjects of the MCNS group not receiving 
corticosteroid therapy (data not shown).
Urinary NAG levels vs urinary 
semaphorin3A levels
We examined the correlation between urinary semaphorin3A 
and urinary NAG. The IgA-N, MN and FSGS groups showed 
significant correlations; however, the MCNS group did not 
show any correlations (Table 3). Generally, most of the IgA-
N, MN and FSGS patients showed chronic disease progres-
sion accompanied by tubulointerstitial damage; therefore, 
semaphorin3A in the renal tubules might have been excreted 
into the urine.
Discussion
Semaphorin3A is reported to be a candidate predictive bio-
marker for AKI or chronic kidney disease severity.14,15 We 
examined the semaphorin3A levels of glomerular disease 
patients. We also tracked the levels of patients with MCNS 
who achieved remission. From these analyses, we recognized 
a drastic decrease in the urinary semaphorin3A from disease 
onset to remission in MCNS patients, suggesting that urinary 
semaphorin3A levels are associated with the activity of MCNS.
A previous report showed that AKI induced the excretion 
of semaphorin3A through urine.14 MCNS often causes tubular 
ischemia that leads to AKI via circulatory disturbance and 
impaired glomerular permeability.17,18 In this study, patients 
with MCNS did not reach an AKI state. We did not observe 
any obvious tubular damage as pathological findings in the 
MCNS group. On the other hand, there were significant 
increase in the urinary NAG level in MCNS, IgA-N and MN 
patients. However, in MCNS group, neither urinary protein 
nor urinary NAG had a significant correlation with urinary 
semaphorin3A. The precise origin of urinary semaphorin3A 
in MCNS could not be determined from our results. However, 
given that semaphorin3A expression is found on podocytes 
and renal tubules, semaphorin3A in urine might represent 
glomerular podocyte disorder, tubulointerstitial damage or 
both. Our results suggested that semaphorin3A might be 
involved in the pathophysiology of MCNS. In addition, the 
evaluation of urinary semaphorin3A levels in MCNS patients 
might be useful for the examination of reactivity toward 
immunosuppressive therapy.
MN and FSGS are also typical glomerular diseases pre-
senting with substantially elevated urinary protein levels, and 
some patients with IgA-N also show high urinary protein lev-
els. The histologic features of nephrotic syndrome include the 
loss of integrity of the foot processes and the slit diaphragm, 
leading to foot process effacement.1
 
The typical slit diaphragm 
structures disappear in nephrotic syndrome, regardless of 
the type of nephropathy.1 Although both MCNS and MN 
often show an increase in glomerular permeability with few 
structural abnormalities on light microscopy, the etiological 
association of immunoglobulin deposits is well documented 
in MN.19,20 Urinary semaphorin3A levels in MCNS, IgA-N 
and MN groups were higher than in control, but only IgA-N 
and MN exhibited the significant correlations between urinary 
NAG levels. In our study, urinary semaphorin3A in IgA-N and 
MN might have mostly reflected the tubulointerstitial dam-
age. MN also showed an increase in serum semaphorin3A. At 
Table 2 Correlations of urinary protein levels with urinary semaphorin3A levels
TBM MCNS IgA-N MN FSGS Control
Number of subjects 4 22 21 16 9 5
Correlation coefficient 0.800
−0.304 0.242 0.409 0.383 0.000
p-value 0.200 0.168 0.291 0.116 0.308 1.000
Abbreviations: FSGS, focal segmental glomerular sclerosis; IgA-N, IgA nephritis; MCNS, minimal change nephrotic syndrome; MN, membranous nephropathy; TBM, thin 
basement membrane disease; r, correlation coefficient.
Table 3 Correlations of urinary NAG levels with urinary semaphorin3A levels
TBM MCNS IgA-N MN FSGS Control
Number of subjects 4 20 21 14 9 5
Correlation coefficient 0.800
−0.041 0.734 0.587 0.683 0.400
p-value 0.200 0.865 0.00015* 0.027* 0.042* 0.565
Note: *p<0.05.
Abbreviations: FSGS, focal segmental glomerular sclerosis; IgA-N, IgA nephritis; MCNS, minimal change nephrotic syndrome; MN, membranous nephropathy; NAG, 
N-acetyl-β-glucosaminidase; TBM, thin basement membrane disease; r, correlation coefficient.
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present, there is little report of human serum semaphorin3A; 
therefore, the significance of serum semaphorin3A is yet to 
be elucidated. The mechanism of increase of serum semapho-
rin3A in MN is not clear. With regard to FSGS, certain non-
immunoglobulin-circulating permeability factors have been 
postulated.21 The difference in these disease mechanisms may 
induce variation in the findings for podocyte disorder, and the 
roles of semaphorin3A at each part of the nephron may also 
differ among diseases. However, this consideration remains 
speculative, and additional research is required.
Only 72 patients were enrolled in this study, mainly 
because most samples were incomplete or unavailable. We 
also did not evaluate any patients with diabetic nephropathy, 
as we usually do not perform renal biopsies on patients who 
demonstrate the clinical features typical of diabetic nephropa-
thy. Therefore, we did not collect sufficient number of samples 
from patients with diabetic nephropathy for this study. In this 
study, the correlation of urinary semaphorin3A level and 
urinary protein in the MCNS group was not significant. The 
small number of subjects might have affected the results. 
Another limitation of this study is that we were only able to 
follow patients with MCNS. Besides, in MCNS, we could 
follow the change of urinary semaphorin3A levels only twice. 
By examining the urinary semaphorin3A levels of patients 
with various glomerular diseases in various disease states, we 
can improve our understanding of the role of semaphorin3A 
in these diseases.
We exhibited the increase of urinary semaphorin3A in 
specific glomerular diseases in this study as already reported 
AKI and CKD. Semaphorin3A has also been reported as 
a candidate therapeutic target in diabetic nephropathy, 
because a semaphorin3A inhibitory peptide was reported 
to ameliorate diabetic nephropathy in an animal model.16 
Applying the findings from pharmacological investigations 
in other glomerular diseases such as MCNS to this disease 
may therefore be useful. Further study is required to clarify 
the role of semaphorin3A in patients with MCNS and other 
renal glomerular diseases in a larger cohort in the future. We 
conclude that urinary semaphorin3A levels correlate with 
the MCNS activity and that urinary semaphorin3A has the 
potential as a biomarker in MCNS treatment for obtaining a 
differential diagnosis from other renal diseases.
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Figure S2 Immunohistochemical analysis for semaphorin3A in the glomerulus and 
renal tubules for each nephropathy.
Notes: (A, C, E, G) Glomerulus, (B, D, F, H) tubules. (A and B) TBM, (C and D) 
IgA-N, (E and F) MN, (G and H) FSGS. Representative figures for each nephropathy. 
The podocytes exhibit partial positive staining in the glomerulus. The renal tubules, 
which appear to be distal or collecting tubules in the absence of a brush border, are 
positively stained. There are no apparent differences in the staining intensity among 
the nephropathies.
Abbreviations: FSGS, focal segmental glomerular sclerosis; IgA-N, IgA nephritis; 
MN, membranous nephropathy; TBM, thin basement membrane disease.
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Figure S1 Urinary NAG and serum semaphorin3A.
Notes: (A) Urinary NAG levels in the MCNS, IgA-N and MN groups are higher 
than in control. *p<0.05, **p<0.01. (B) Serum semaphorin3A levels in the MCNS 
and MN groups are higher than in control. *p<0.05, **p<0.01.
Abbreviations: FSGS, focal segmental glomerular sclerosis; IgA-N, IgA nephritis; 
MCNS, minimal change nephrotic syndrome; MN, membranous nephropathy; NAG, 
N-acetyl-β-glucosaminidase; TBM, thin basement membrane disease.
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Figure S3 Immunohistochemical analysis for neuropilin-1 in the glomerulus and 
renal tubules for each nephropathy.
Notes: (A, C, E, G) Glomerulus, (B, D, F, H) tubules. (A and B) TBM, (C and D) 
IgA-N, (E and F) MN, (G and H) FSGS. Representative figures for each nephropathy. 
The podocytes exhibit 2 partial positive staining in the glomerulus. The renal tubules, 
which appear to be distal or collecting tubules in the absence of a brush border, are 
positively stained. There are no apparent differences in the staining intensity among 
the nephropathies.
Abbreviations: FSGS, focal segmental glomerular sclerosis; IgA-N, IgA nephritis; 
MN, membranous nephropathy; TBM, thin basement membrane disease.
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